Question 1

What can the Click.mAb. platform do?

Accepted Answer

Click.mAb. is a multi-agent AI antibody design platform developed by Clickmab. Core capabilities include: de novo antibody design for specific epitopes, epitope prediction, antibody/nanobody humanization, and affinity maturation. It supports the full workflow from natural language R&D goals to AI-driven task decomposition, tool orchestration, and structured report generation.

Question 2

What is the success rate of de novo design? Is there experimental validation?

Accepted Answer

Validated on 4 targets. After designing ~10,000 candidates for specified epitopes, wet-lab validation yielded multiple hits with affinity ranging from μM to nM. The best case produced 7 BLI-positive antibodies (KD 10⁻⁶~10⁻⁸ M), 2 with ligand-blocking function, confirmed by cryo-EM.

Question 3

What is the accuracy of epitope prediction?

Accepted Answer

Our INSPIRE-SEEN model achieves 78% patch binary classification accuracy on 110 known epitopes, a 28-point improvement over AlphaFold2-Multimer's 50%. Each prediction takes ~15 minutes at over 100x lower cost than traditional wet-lab methods.

Question 4

What are the advantages of AI affinity maturation?

Accepted Answer

Compared to traditional random mutagenesis, AI affinity maturation uses structure-aware models to precisely predict beneficial mutations, requiring fewer candidates to cover high-gain designs and dramatically reducing wet-lab rounds. It also balances stability and developability to avoid aggregation or expression issues.

Question 5

How does AI antibody design differ from traditional animal immunization?

Accepted Answer

Traditional methods rely on animal immunization, favoring immunodominant epitopes with limited coverage of cryptic or low-immunogenicity epitopes. AI de novo design bypasses immunization entirely, generating novel antibodies directly targeting specified epitopes for precise rational design.

Question 6

How effective is humanization?

Accepted Answer

Antibody humanization achieves 90%–95% humanness with zero back-mutations needed, requiring only 10–20 candidates. Nanobody humanization reaches 89%–94%, with 4 out of 7 recommended sequences showing improved affinity, best improving from 16 nM to ~4 nM.

Question 7

What data is needed to use the platform?

Accepted Answer

Input varies by module: de novo design requires antigen structure and target epitope; epitope prediction needs antigen structure (PDB) and antibody sequences (VH/VL); humanization needs variable region sequences; affinity maturation needs antigen and antibody sequences. The platform guides you through input.

Question 8

How to get started?

Accepted Answer

Visit clickmab.com to register and try epitope prediction and de novo design online. For full project collaboration (including wet-lab validation), contact our business team at bd@clickmab.com for a customized solution.

Click.mAb.
Multi-Agent AI Antibody Design Platform

Core Algorithm Capabilities, Breaking Key Bottlenecks

Lightweight Tools

Epitope Prediction

De Novo Antibody Design

Affinity Maturation

Antibody Humanization

Nanobody Humanization

Conversational AI, Zero Learning Curve

One Sentence to Launch R&D

Project-Level Management for Team Collaboration

Parallel Multi-Track Progress

Independent Verification & Collaborative Advancement

Auto-Aggregated Project Knowledge Base

Reviewable · Traceable · Transferable

A Complete Loop from Candidate Generation to Validation

Epitope-Directed Design

Structure and Sequence Assessment

Wet-Lab Continuity

Project Review

FAQ

Start Your AI-Driven Antibody R&D Journey